Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC

Ernst, Sophie M.; Mankor, Joanne; Riet, Job van; Thüsen, Jan H. von der; Dubbink, Hendrikus J.; Aerts, Joachim; Langen, Adrianus J. de; Smit, Egbert F.; Dingemans, Anne‐Marie C.; Monkhorst, Kim

doi:10.1016/j.jtho.2022.11.030

Cited by 23 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Smoking history [ 18 , 19 ], indoor cooking [ 20 , 21 ], air pollution exposure (e.g., PM2.5) [ 22 , 23 ], and exposure to toxic chemicals (e.g., radon, asbestos, and arsenic) [ 24 , 25 ] have been reported as key factors in the incidence of NSCLC. However, except for the smoking history discussed broadly in several research [ [26] , [27] , [28] ] and this study, other factors are challenging to quantify at the level of a certain individual, which made it difficult to accurately determine the correlation and potential mechanisms between geographic or environmental factors and certain types of gene mutations. In the future, larger cohorts and better consideration of patient information collection may make systematic analysis possible.…”

Section: Discussionmentioning

confidence: 99%

Different gene alterations in patients with non-small-cell lung cancer between the eastern and southern China

Liu,

Li,

Sui

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Different gene alterations in patients with non-small-cell lung cancer between the eastern and southern China

Liu,

Li,

Sui

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Sin embargo, se ha demostrado que las mutaciones accionables se pueden encontrar en CPCNP más allá de la histología, el hábito tabáquico y la edad 3 . Por ejemplo, las mutaciones en BRAF, amplificaciones en MET y mutaciones en KRAS fueron detectadas en mayor proporción en tabaquistas que en no tabaquistas 5 .…”

Section: Conclusion: Considering Both Cohorts 60%unclassified

Tiempo al acceso al tratamiento dirigido en cáncer de pulmón de células no pequeñas no escamoso metastásico

Freile,

Coria,

Vargas

et al. 2024

RevOnco

View full text Add to dashboard Cite

El descubrimiento de alteraciones moleculares accionables y su tratamiento dirigido ha mejorado el pronóstico del CPNCP metastásico (1). El acceso al testeo y al tratamiento dirigido representa una limitación en nuestro país. En este estudio retrospectivo, el objetivo es describir el tiempo a la demora entre la solicitud del testeo molecular y el inicio de tratamiento dirigido en CPNCP metastásico no escamoso con mutación accionable en primera línea. Se incluyeron pacientes entre 01/2018 y 10/2022, con registro de fecha exacta de inicio de tratamiento. Se consideran dos cohortes, según el tipo de testeo utilizado, el molecular individual o el panel multigenético. Entre los 437 pacientes que fueron testeados, 76.2% utilizaron testeo molecular individual y 23.79% panel multigenético. Entre los pacientes con testeo individual, el 22.2% tuvo mutación accionable. Entre los que accedieron al tratamiento dirigido, la mediana de demora al inicio tras la solicitud del testeo molecular fue de 22 días (RIC: 15.5-30.5). En cuanto a los que se realizaron panel multigenético, en el 57.7% se detectó una mutación accionable, la mediana de días de inicio del tratamiento tras la solicitud del testeo fue de 36.5 días (RIC: 30-51). Considerando ambas cohortes, hay acceso de aproximadamente el 60% al tratamiento dirigido en primera línea. Una vez identificada la mutación la cobertura no genera una demora mayor para la aprobación del tratamiento.

show abstract

“…In the future, sequencing of the entire exome or genome in combination with the transcriptome will expand, raising further challenges in terms of analyses, turnaround time, data storage capacity, and the expertise of the molecular pathologist [ 84 , 85 ]. The genomic signatures will likely become increasingly complex to interpret, resulting in new classifications [ 86 – 91 ]. In this context we need to keep in mind that RNA-based NGS has also emerged as a more clinically sensitive approach than DNA-based NGS for the detection of both fusions and splice variants [ 15 ].…”

Section: Short- and Mid-term Perspectivesmentioning

confidence: 99%

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Hofman,

Berezowska,

Kazdal

et al. 2023

Virchows Arch

View full text Add to dashboard Cite

The continuing evolution of treatment options in thoracic oncology requires the pathologist to regularly update diagnostic algorithms for management of tumor samples. It is essential to decide on the best way to use tissue biopsies, cytological samples, as well as liquid biopsies to identify the different mandatory predictive biomarkers of lung cancers in a short turnaround time. However, biological resources and laboratory member workforce are limited and may be not sufficient for the increased complexity of molecular pathological analyses and for complementary translational research development. In this context, the surgical pathologist is the only one who makes the decisions whether or not to send specimens to immunohistochemical and molecular pathology platforms. Moreover, the pathologist can rapidly contact the oncologist to obtain a new tissue biopsy and/or a liquid biopsy if he/she considers that the biological material is not sufficient in quantity or quality for assessment of predictive biomarkers. Inadequate control of algorithms and sampling workflow may lead to false negative, inconclusive, and incomplete findings, resulting in inappropriate choice of therapeutic strategy and potentially poor outcome for patients. International guidelines for lung cancer treatment are based on the results of the expression of different proteins and on genomic alterations. These guidelines have been established taking into consideration the best practices to be set up in clinical and molecular pathology laboratories. This review addresses the current predictive biomarkers and algorithms for use in thoracic oncology molecular pathology as well as the central role of the pathologist, notably in the molecular tumor board and her/his participation in the treatment decision-making. The perspectives in this setting will be discussed.

show abstract

Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC

Cited by 23 publications

References 42 publications

Different gene alterations in patients with non-small-cell lung cancer between the eastern and southern China

Different gene alterations in patients with non-small-cell lung cancer between the eastern and southern China

Tiempo al acceso al tratamiento dirigido en cáncer de pulmón de células no pequeñas no escamoso metastásico

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Contact Info

Product

Resources

About